Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma

Activating KRAS mutations occur in about 30% of pulmonary adenocarcinoma (AC) cases and the discovery of specific inhibitors of G12C-mutated KRAS has considerably improved the prognosis for a subgroup of about 14% of non-small cell lung cancer (NSCLC) patients. However, even in patients with a KRAS...

Full description

Bibliographic Details
Main Authors: Yuchan Li, Omar Elakad, Sha Yao, Alexander von Hammerstein-Equord, Marc Hinterthaner, Bernhard C. Danner, Carmelo Ferrai, Philipp Ströbel, Stefan Küffer, Hanibal Bohnenberger
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Metabolites
Subjects:
one-carbon metabolism
MTHFD2
KRAS
EZH2
pulmonary adenocarcinoma
Online Access:https://www.mdpi.com/2218-1989/12/7/652

Similar Items

Similar Items